HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Haynie, T. P. Articles by Glenn, H. J. Search for Related Content PubMed PubMed Citation Articles by Haynie, T. P. Articles by Glenn, H. J.

Technetium-99m Stannous Citrate Brain-Tumor Uptake in Mice: Concise Communication

The University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute, Houston, Texas

Correspondence: For reprints contact: Thomas P. Haynie, The University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute, 6723 Bertner Dr., Houston, TX 77030.

ABSTRACT

The pharmacodynamics of technetium-99m stannous citrate were studied in Yale-Swiss mice bearing a sarcoma-like transplantable brain tumor, and the renal kinetics were determined in normal mice. Using a rating system based on tumor uptake and tumor-to-brain, tumor-to-blood, and tumor-to-skin ratios, the data obtained with this compound were compared with similar data obtained previously in the same model with Tc-99m Fe-(ascorbic acid), Tc-99m Fe-(ascorbic acid)-DTPA, Tc-99m Sn-DTPA, [^99mTc] pertechnetate, and [^99mTc] pertechnetate with perchlorate predose. Technetium-99m stannous citrate does not appear to achieve tumor localization by a mode different from these other Tc-99m-labeled compounds, nor does it show any potential advantage as a scanning agent in this tumor model.